Skip to main content

Table 1 Demographic characteristics of 4446 patients with limited-disease small-cell lung cancer who received definite concurrent chemoradiotherapy

From: Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study

Variables

LD stage (n = 4446)

Age, years

64 ± 8.28

 < 65

2187 (49.2)

 ≥65

2259 (50.8)

Sex (male/female)

3797 (85.4)/649 (14.6)

Comorbidities

 HBP

2361 (39.3)

 DM

1334 (22.2)

 Hypercholesterolemia

2314 (38.5)

First-line therapy

 Combination CRT

  Etoposide/platinum

4187 (94.2)

  Irinotecan/platinum

259 (5.8)

Second-line therapy

 Combination therapy

  Etoposide/platinum

151 (8.7)

  Irinotecan/platinum

774 (44.5)

 Single-agent therapy

  Etoposide

1 (0.1)

  Irinotecan

232 (13.3)

  Belotecan

342 (19.6)

  Topotecan

240 (13.8)

  1. Values are presented as mean ± standard deviation or number (%)
  2. LD, limited disease; HBP, hypertension; DM, diabetes mellitus; CRT, chemoradiotherapy
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us